(S)-3-(4-iodophenyl)-5-pyrrolidin-2-yl-1,2,4-oxadiazole | 1449767-25-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (S)-3-(4-iodophenyl)-5-pyrrolidin-2-yl-1,2,4-oxadiazole
• 英文别名: 3-(4-iodophenyl)-5-[(2S)-pyrrolidin-2-yl]-1,2,4-oxadiazole
• CAS: 1449767-25-2
• 化学式: C₁₂H₁₂IN₃O
• 分子量: 341.151
• InChiKey: UTZQLGJATVIVAW-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  51
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-3-(4-iodophenyl)-5-pyrrolidin-2-yl-1,2,4-oxadiazole 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 72.0h， 生成 (S)-amino(2-(3-(4-iodophenyl)-1,2,4-oxadiazol-5-yl)pyrrolidin-1-yI)methaniminium chloride
  参考文献：
  名称：

  Structure–activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors

  摘要：

  Sphingosine-1-phosphate (S1P) is a ubiquitous, endogenous small molecule that is synthesized by two isoforms of sphingosine kinase (SphK1 and 2). Intervention of the S1P signaling pathway has attracted significant attention because alteration of S1P levels is linked to several disease states including cancer, fibrosis, and sickle cell disease. While intense investigations have focused on developing SphK1 inhibitors, only a limited number of SphK2-selective agents have been reported. Herein, we report our investigations on the structure-activity relationship studies of the lipophilic tail region of SLR080811, a SphK2-selective inhibitor. Our studies demonstrate that the internal phenyl ring is a key structural feature that is essential in the SLR080811 scaffold. Further, we show the dependence of SphK2 activity and selectivity on alkyl tail length, suggesting a larger lipid binding pocket in SphK2 compared to SphK1. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.03.041
• 作为产物：
  描述：

  4-碘氰基苯 在 盐酸 、 6-chloro-3-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazol-3-ium-1-olatehexafluorophosphate(V) 、 盐酸羟胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 (S)-3-(4-iodophenyl)-5-pyrrolidin-2-yl-1,2,4-oxadiazole
  参考文献：
  名称：

  Structure–activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors

  摘要：

  Sphingosine-1-phosphate (S1P) is a ubiquitous, endogenous small molecule that is synthesized by two isoforms of sphingosine kinase (SphK1 and 2). Intervention of the S1P signaling pathway has attracted significant attention because alteration of S1P levels is linked to several disease states including cancer, fibrosis, and sickle cell disease. While intense investigations have focused on developing SphK1 inhibitors, only a limited number of SphK2-selective agents have been reported. Herein, we report our investigations on the structure-activity relationship studies of the lipophilic tail region of SLR080811, a SphK2-selective inhibitor. Our studies demonstrate that the internal phenyl ring is a key structural feature that is essential in the SLR080811 scaffold. Further, we show the dependence of SphK2 activity and selectivity on alkyl tail length, suggesting a larger lipid binding pocket in SphK2 compared to SphK1. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.03.041

文献信息

• LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS
  申请人：UNIVERSITY OF VIRGINIA PATENT FOUNDATION

  公开号：US20150210675A1

  公开（公告）日：2015-07-30

  The invention relates to inhibitors of Sphingosine Kinase enzymatic activity, and methods of treating diseases and disorders by administering inhibitors of Sphingosine Kinase enzymatic activity.

  本发明涉及抑制鞘氨醇激酶酶活性的抑制剂，以及通过给予鞘氨醇激酶酶活性抑制剂治疗疾病和疾患的方法。
• US9688668B2
  申请人：——

  公开号：US9688668B2

  公开（公告）日：2017-06-27
• [EN] LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA KINASE SPHINGOSINE AVEC BASE À LONGUE CHAÎNE
  申请人：UNIVERSITY OF VIRGINIA PATENT FOUNDATION

  公开号：WO2013119946A1

  公开（公告）日：2013-08-15

  The invention relates to inhibitors of sphingosine kinase enzymatic activity, compounds and pharmaceutical compositions that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) enzymes and further relates to methods of treating diseases and disorders mediated by sphingosine 1 phosphate activity, comprising administering an effective amount of sphingosine kinase inhibitors.